HPV Genotyping Panels Market Seen Reaching $2.07 Billion by 2030

The global HPV genotyping panels market is projected to grow from $1.79 billion in 2025 to $2.07 billion by 2030, driven by rising HPV infections, cervical cancer screening, and wider use of molecular diagnostics. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth through 2030.

Why it matters: - HPV genotyping panels are becoming a bigger part of cancer screening and early diagnosis as HPV-linked cancers rise worldwide. - The market growth points to more demand for molecular diagnostics, laboratory infrastructure, and population screening programs. - Cervical cancer remains a major public health issue, with global new cases and deaths cited as rising sharply by 2050.

What happened: - The Business Research Company said the human papillomavirus (HPV) genotyping panels market is projected to rise from $1.79 billion in 2025 to $1.84 billion in 2026. - The same report forecasts the market will reach $2.07 billion by 2030. - The report also projects a 2.7% CAGR from 2025 to 2026 and a 3.0% CAGR through 2030. - The company published the findings in its Human Papillomavirus (HPV) Genotyping Panels Market Report 2026. - The report includes a free sample and a full version available online: Download a free sample and View the full market report.

The details: - The report ties growth to widespread HPV infections, higher awareness of cervical cancer screening, and expansion of molecular diagnostic laboratory infrastructure. - Government-funded screening initiatives and rising use of PCR-based diagnostic methods are also listed as growth drivers. - HPV-associated cancers cited in the report include cervical, oropharyngeal, anal, vulvar, and penile cancers. - The report says persistent infection with high-risk HPV strains drives many of these cancers. - The National Institutes of Health reported that cervical cancer accounted for about 662,044 new cases and 348,709 deaths globally in 2022. - The report says those figures are expected to rise 56.8% and 80.7%, respectively, by 2050. - The American Medical Association reported that U.S. health spending grew 7.5% in 2023 to $4.9 trillion, or $14,570 per person. - The report cites higher healthcare spending as a support for advanced diagnostics and screening. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The geographic coverage also includes South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The forecast suggests HPV testing is moving from a specialized diagnostic segment toward a more embedded role in routine cancer prevention. - The regional split implies mature markets will likely expand more slowly, while countries increasing screening access could drive the next wave of growth. - The report’s emphasis on infrastructure and funding shows this market depends as much on health-system adoption as on clinical need.

What's next: - The report expects continued demand from screening programs, molecular diagnostics adoption, and rising HPV-related cancer burden. - Asia-Pacific’s faster growth outlook suggests more investment and diagnostic uptake in that region could become a major market catalyst. - The Business Research Company says its Global Market Model will continue to support updated forecasting and market tracking.

The bottom line: - HPV genotyping panels are positioned for steady, policy-linked growth through 2030 as cancer screening and diagnostic capacity expand.